Tragara announced the completion of patient enrollment to its APRiCOT-L study, a Phase 2 trial of its anti-cancer agent, Capoxigem (apricoxib, TG01), in non-small cell lung cancer (NSCLC). This study is a randomized, double-blind, multi-center, placebo-controlled trial designed to evaluate Capoxigem in combination with erlotinib in second and third line NSCLC patients that have failed a platinum-containing regimen. The primary efficacy endpoint of the APRiCOT-L study is to compare the time to progression (TTP) between the Capoxigem/erlotinib arm and the placebo/erlotinib arm. Secondary objectives include progression-free survival, response rate, duration of response, overall survival and measures of symptom relief.
Capoxigem is an oral, once-daily selective COX-2 inhibitor. As an anti-cancer treatment, Capoxigem affects a number of different oncogenic signaling pathways, including the HIF-1, VEGF, VEGF-R and PDGF systems for angiogenesis; the EGFR, HER2/neu, Bcr/Abl for growth control and differentiation; the intrinsic and extrinsic pathways for apoptosis; and the integrin and metalloproteinase systems for tissue invasion and metastasis.
For more information call (858) 350-6900 or visit www.tragarapharma.com.